Skip to main content
. 2017 Aug 3;65(11):1780–1790.e1. doi: 10.1093/cid/cix685

Table 1.

Invasive pneumococcal disease incidence after PCV10/13 vaccination compared to before PCV7 and PCV10/13 vaccination according to serotype and age group in the whole of Sweden

Age group (years) Serotype Pre-PCV7 Incidenceb (2007) Pre-PCV10/13 Incidenceb (2007–2009) Post-PCV10/13 Incidenceb (2013–2016) Post-PCV10/13 vs. Pre-PCV7 Rate Ratio (95% CI)c Post-PCV10/13 vs. Pre-PCV10/13 Rate Ratio (95% CI)c
0–4 (N = 73) (N = 210) (N = 120)
All serotypes 13.9 (11.0,17.5) 13.0 (11.4,14.9) 5.1 (4.3,6.1) 0.37 (0.28,0.49) 0.39 (0.31,0.49)
4,6B,9V,14, 18C,19F,23F 9.4 (7.0,12.5) 7.9 (6.5,9.6) 0.4 (0.2,0.9) 0.05 (0.02,0.1) 0.06 (0.03,0.11)
1,5,7F 1.4 (0.6,2.8) 1.6 (1.0,2.3) 0.1 (0.02,0.4) 0.07 (0.01,0.35) 0.06 (0.01,0.27)
1 0 (0.0,0.7)a 0.1 (0.03,0.5) 0 (0,0.2)a - 0 (0,2.4)a
7F 1.4 (0.6,2.8) 1.4 (0.9,2.2) 0.1 (0.02,0.4) 0.07 (0.01,0.35) 0.07 (0.01,0.3)
3,6A,19A 2.1 (1.1,4.1) 2.1 (1.4,3.1) 1.3 (0.9,1.9) 0.62 (0.3,1.28) 0.62 (0.37,1.08)
3 0.2 (0.03,1.8) 0.6 (0.3,1.2) 0.7 (0.4,1.1) 2.85 (0.36,22.8) 1.2 (0.47,3.1)
6A 1.2 (0.5,2.6) 0.7 (0.4,1.2) 0.1 (0.02,0.34) 0.07 (0.01,0.36) 0.13 (0.03,0.59)
19A 0.7 (0.2,2.3) 0.9 (0.5,1.7) 0.6 (0.3,1.0) 0.81 (0.22,3.0) 0.64 (0.28,1.49)
NVT 1.0 (0.3,3.1) 1.4 (0.8,2.5) 3.2 (2.6,4.1) 3.41 (1.02,11.4) 2.27 (1.26,4.1)
5–64 (N = 648) N = (2097) (N = 1794)
All serotypes 9.2 (8.5,9.9) 9.9 (9.5,10.3) 6.1 (5.9,6.4) 0.67 (0.61,0.73) 0.62 (0.58,0.66)
4,6B,9V,14, 18C,19F,23F 4.7 (4.2,5.3) 4.7 (4.4,5.1) 0.5 (0.4,0.6) 0.1 (0.08,0.13) 0.1 (0.09,0.13)
1,5,7F 1.4 (1.1,1.8) 1.9 (1.7,2.1) 0.5 (0.5,0.6) 0.38 (0.29,0.51) 0.29 (0.24,0.35)
1 0.2 (0.1,0.4) 0.4 (0.3,0.5) 0.1 (0.06,0.1) 0.39 (0.20,0.73) 0.26 (0.16,0.40)
7F 1.2 (0.9,1.5) 1.5 (1.3,1.7) 0.4 (0.4,0.5) 0.37 (0.27,0.51) 0.29 (0.23,0.36)
3,6A,19A 1.3 (1.0,1.6) 1.3 (1.1,1.5) 1.5 (1.3,1.6) 1.18 (0.91,1.52) 1.14 (0.97,1.35)
3 0.8 (0.5,1.0) 0.8 (0.6,0.9) 0.9 (0.8,1.0) 1.22 (0.88,1.73) 1.23 (0.99,1.54)
6A 0.3 (0.2,0.5) 0.3 (0.2,0.4) 0.03 (0.02,0.07) 0.1 (0.04,0.24) 0.12 (0.05,0.27)
19A 0.1 (0.06,0.3) 0.3 (0.2,0.3) 0.5 (0.4,0.6) 3.52 (1.51,8.21) 2.03 (1.42,2.91)
NVT 1.8 (1.4,2.2) 2.0 (1.7,2.2) 3.6 (3.4,3.9) 2.0 (1.65,2.52) 1.85 (1.62,2.11)
≥65 (N = 738) (N = 2545) (N = 3168)
All serotypes 45.9 (42.7,49.3) 51.5 (49.5,53.5) 41.1 (39.7,42.6) 0.9 (0.83,0.97) 0.8 (0.76,0.84)
4,6B,9V,14, 18C,19F,23F 24.3 (21.8,27.1) 25.4 (23.7,27.1) 2.8 (2.5,3.3) 0.12 (0.1,0.14) 0.11 (0.1,0.13)
1,5,7F 3.3 (2.4,4.6) 3.5 (2.9,4.2) 1.3 (1.1,1.7) 0.4 (0.27,0.6) 0.38 (0.29,0.51)
1 0.2 (0.06,0.6) 0.3 (0.2,0.6) 0.1 (0.04,0.2) 0.53 (0.13,2.13) 0.3 (0.11,0.86)
7F 3.0 (2.1,4.2) 3.1 (2.6,3.8) 1.2 (1.0,1.5) 0.41 (0.28,0.61) 0.39 (0.29,0.53)
3,6A,19A 8.4 (7.0,10.2) 9.7 (8.8,10.7) 9.8 (9.1,10.6) 1.16 (0.95,1.42) 1.01 (0.89,1.14)
3 4.6 (3.5,5.9) 4.8 (4.1,5.5) 6.2 (5.6,6.8) 1.36 (1.04,1.77) 1.3 (1.09,1.55)
6A 2.7 (2.0,3.7) 3.1 (2.6,3.7) 0.5 (0.4,0.7) 0.2 (0.12,0.31) 0.17 (0.12,0.25)
19A 1.2 (0.6,2.2) 1.8 (1.4,2.4) 3.1 (2.7,3.5) 2.67 (1.38,5.15) 1.68 (1.26,2.24)
NVT 9.8 (8.2,11.8) 12.8 (11.7,14.1) 27.1 (25.9,28.2) 2.76 (2.28,3.34) 2.11 (1.9,2.34)
All age groups (N = 1459) (N = 4852) (N = 5082)
All serotypes 15.9 (15.1,16.7) 17.5 (17.0,18.0) 13.0 (12.6,13.3) 0.82 (0.77,0.86) 0.74 (0.71,0.77)
4, 6B, 9V, 14, 18C,19F, 23F 8.4 (7.8,9.1) 8.6 (8.2,9.0) 1.0 (0.9,1.1) 0.11 (0.1,0.13) 0.11 (0.1,0.12)
1,5,7F 1.7 (1.5,2.0) 2.2 (2.0,2.3) 0.7 (0.6,0.8) 0.39 (0.31,0.47) 0.31 (0.27,0.37)
1 0.2 (0.1,0.4) 0.3 (0.3,0.4) 0.09 (0.06,0.13) 0.41 (0.23,0.72) 0.26 (0.17,0.39)
7F 1.5 (1.3,1.8) 1.8 (1.6,2.0) 0.6 (0.5,0.7) 0.38 (0.3,0.48) 0.32 (0.27,0.38)
3,6A,19A 2.6 (2.2,2.9) 2.8 (2.6,3.1) 3.1 (2.9,3.3) 1.21 (1.04,1.41) 1.09 (0.99,1.2)
3 1.4 (1.1,1.7) 1.5 (1.3,1.6) 1.9 (1.8,2.1) 1.4 (1.13,1.72) 1.34 (1.17,1.54)
6A 0.8 (0.6,1.0) 0.8 (0.7,0.9) 0.13 (0.1,0.19) 0.17 (0.11,0.25) 0.17 (0.12,0.24)
19A 0.4 (0.2,0.6) 0.6 (0.5,0.7) 1.0 (0.9,1.1) 2.87 (1.69,4.85) 1.79 (1.43,2.24)
NVT 3.1 (2.7,3.6) 3.9 (3.6,4.2) 8.2 (7.9,8.5) 2.61 (2.26,3.02) 2.12 (1.96,2.3)

aThese calculations were made by using an exact method on the observed data.

bIncidence per 100000 population in year (95% Confidence Interval)

cSignificant changes in rate ratios in bold